ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0328 • ACR Convergence 2024

    IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease

    Melissa Leeolou1, Lorinda Chung2, Kavita Sarin3 and david fiorentino4, 1Stanford University School of Medicine, Redwood City, CA, 2Stanford University, Woodside, CA, 3Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 4Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA

    Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity.  Melanoma differentiation-associated gene 5…
  • Abstract Number: 0264 • ACR Convergence 2024

    Clinical Value of Metagenomic Next-generation Sequencing in Patients with Connective Tissue Disease Co-infections: A Single-center Study from Southern Hospital in China

    Yuan-Yuan Xiao1, Ai-Ling Lu1, Han-You Mo2, Zhen-Dong He2, Jia-Le Wen2 and Xuan Yin1, 1Guilin Medical University, Guilin, China (People's Republic), 2The First Affiliated Hospital of Guangxi Medical University, Nanning, China (People's Republic)

    Background/Purpose: Few studies have been reported on the use of metagenomic next-generation sequencing (mNGS) in patients with connective tissue disease (CTD) co-infections, and more relatively large-scale data…
  • Abstract Number: 0278 • ACR Convergence 2024

    Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study

    Yu Xue1, Tianshu Chu2, Jiankang Hu3, Wei Gou4, Ning Zhang5, Juan Li6, Jing Yu7, Songping Li8, Songbin Li9, Long Qian10, Xinwang Duan11, Lihua Duan12 and Hejian Zou1, 1Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), 2Department of Rheumatology, Henan Provincial People's Hospital, Zhengzhou, China, Zhengzhou, China (People's Republic), 3Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), 4Department of Rheumatology, Hebei Petro China Central Hospital, Langfang, China, Langfang, China (People's Republic), 5Department of Rheumatology, Shengjing Hospital of China Medical University, Shenyang, China, Shenyang, China (People's Republic), 6Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Haikou, China, Haikou, China (People's Republic), 7Department of Rheumatology, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China, Shenyang, China (People's Republic), 8Department of Rheumatology, The First Affiliated Hospital of Ganna Medical University, Ganzhou, China, Ganzhou, China (People's Republic), 9Department of Rheumatology, The First Hospital of Qiqihar, Qiqihar, China, Qiqihar, China (People's Republic), 10Department of Rheumatology, The Second Hopital of Anhui Medical University, Hefei, China, Hefei, China (People's Republic), 11Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, Nanchang, China (People's Republic), 12Department of Rheumatology, Jiangxi Provincial People's Hospital, Nanchang, China, Nanchang, China (People's Republic)

    Background/Purpose: The GUARD (Genakumab in high Uric Acid-induced Arthritis/goutfor Resolution and Delay study) program was designed to investigate the efficacy and safety of Genakumab, a…
  • Abstract Number: 0312 • ACR Convergence 2024

    The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy

    Kristen Caldwell1, Sindhuja Koppu1, Huzaefah Syed2, Aamer Syed1, Jordana Kron1, Thomas Iden1 and Kelly Gwathmey1, 1Virginia Commonwealth University, Richmond, VA, 2Virginia Commonwealth University Medical Center, Richmond, VA

    Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to…
  • Abstract Number: 0348 • ACR Convergence 2024

    Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies

    Ting Zhang1, Qiyuan Wang2, Wenjia Sun3, Lei Liu1 and Jing Xue4, 1Zhejiang University, Hangzhou, China (People's Republic), 2Zhejiang Univerisity, Hangzhou, China (People's Republic), 3The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China (People's Republic), 4The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic)

    Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in idiopathic inflammatory myopathies (IIM), substantially contributing to the morbidity and mortality. ILD…
  • Abstract Number: 0240 • ACR Convergence 2024

    Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study

    Hilde S. Ørbo1, Asia-Sophia Wolf2, Taissa M. Kasahara3, Kristin H. Bjørlykke4, Ingrid Jyssum5, Joseph Sexton5, Anne Therese Tveter5, Guri Solum2, Ingrid Fadum Kjønstad2, Ingrid E. Christensen5, Tore K. Kvien6, Jørgen Jahnsen7, Espen A. Haavardsholm1, Ludvig A. Munthe8, Sella A. Provan5, John Torgils Vaage8, Kristin K. Jørgensen4, Gunnveig Grødeland8, Siri Mjaaland2, Silje W. Syversen9 and Guro L. Goll9, 1Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 2Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, 3University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 4Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 7Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, 8Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
  • Abstract Number: 0266 • ACR Convergence 2024

    Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol

    Dansoa Tabi-Amponsah1, Lisa Stamp2, Anne Horne3, Jill Drake4, Sarah Stewart5, Gregory Gamble3, Keith Petrie1 and Nicola Dalbeth3, 1The University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5Auckland University of Technology, Auckland, New Zealand

    Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
  • Abstract Number: 0307 • ACR Convergence 2024

    Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes

    Sanat Phatak1, Rucha Wagh2, Smita Dhadge2, Sarita Jadhav2, Parth Ladha3, Rishi Nalkande4, Rohan Shah2, Jennifer Ingram5 and Chittaranjan Yajnik2, 1KEM Hospital Research Centre, Pune, Maharashtra, India, 2KEM Hospital Research Centre, Pune, India, 3Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India, 4BJ Government Medical College, Pune, India, 5Duke University Medical Center, Durham, NC

    Background/Purpose: Hand manifestations (limited joint mobility, [LJM]; flexor tenosynovitis, [FT]; carpal tunnel syndrome, [CTS]; Dupuytren disease, [DD]) are common complications in diabetes. Despite their heterogeneity…
  • Abstract Number: 0322 • ACR Convergence 2024

    Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging

    Julie Paik1, Shadi Ayoumi2, Ghazal Zandieh2, Cody Calhoun2, Caoilfhionn Connolly2, Lisa Christopher-Stine1, Christopher Mecoli1, Myma Albayda2, Eleni Tiniakou3, Nisha Gilotra2, Stefan Zimmerman2 and Bharath Venkatesh2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Johns Hopkins University, Lutherville Timonium, MD

    Background/Purpose: Myocarditis in idiopathic inflammatory myopathies (IIM) is poorly understood despite its association with poor outcomes such as heart failure and sudden cardiac death. It…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 0340 • ACR Convergence 2024

    Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease

    Yu-Wan Liao1, Ming-Cheng Liu1, Pin-Kuei Fu1 and Wen-Nan Huang2, and Integrated Care Center of Interstitial Lung Disease, 1Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 2Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China)

    Background/Purpose: Myositis-associated interstitial lung disease (MA-ILD) is a complex condition with a variable prognosis and diverse clinical manifestations. The 2022 ATS/ERS/JRS/ALAT criteria for PPF provide…
  • Abstract Number: 0250 • ACR Convergence 2024

    Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies

    Beiming Wang1, Shi Chen2, Xiaoqing Liu3 and Lifan Zhang3, 1Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Division of Infectious Diseases, Department of Internal medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Peking union medical college hospital, Beijing, China

    Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…
  • Abstract Number: 0349 • ACR Convergence 2024

    Impact of the Stanford University Chronic Pain Self-Management Education Program on Pain Severity, Pain Self-Efficacy, and Pain Disability in a Population with a High Prevalence of Arthritis

    Dina Jones1, Louise Murphy2, Ranjita Misra1, Teresa Brady3, Sijin Wen1, Dana Guglielmo4, Maura Robinson1, Samantha Shawley-Brzoska1, Chong Li1, Alison Vargovich5, Megan Burkart6 and Richard Vaglienti1, 1West Virginia University, Morgantown, WV, 2Consultant, Halifax, NS, Canada, 3Clarity Consulting and Communications, Atlanta, GA, 4Consultant, Los Angeles, CA, 5Private Practice, Buffalo, NY, 6West Virginia Unviverstiy, Morgantown, WV

    Background/Purpose: In 2021, 51.6 million (20.9%) US adults reported chronic pain (CP). Arthritis is a leading cause of CP. The Stanford Chronic Pain Self-Management Program…
  • Abstract Number: 0331 • ACR Convergence 2024

    Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

    Sangmee Bae1, Gianluca sambataro2, iazsmin Ventura3, Francisca Bozan4, Eduardo Dourado5, Sara Faghihi-Kashani6, Aravinthan Loganathan7, Daphne Rivero Gallegos8, Akira Yoshida9, Giovanni Zanframundo10, Francesco Bonella11, Tamera J Corte12, Tracy J Doyle13, david fiorentino14, Miguel Angel Gonzalez-Gay15, marie Hudson16, Masataka Kuwana17, Andrew Mammen18, Neil McHugh19, Frederick Miller20, Carlomaurizio Montecucco21, Antonella Notarnicola22, Chester Oddis23, Jorge Rojas-Serrano24, Jens Schmidt25, Carlo A. Scire26, Albert Gil-Vila27, Victoria Werth28, Lorenzo Cavagna29 and Rohit Aggarwal30, 1UCLA, Los Angeles, CA, 2University of Catania, Catania, Italy, 3Section of Rheumatology, University of Chicago, Chicago, IL, 4Hospital Clinico Universidad de Chile, Santiago, Chile, 5Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, 6Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8INER, Ciudad de México, Mexico State, Mexico, 9Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 10Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, 11Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, 12Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, 13Brigham and Women's Hospital, West Roxbury, MA, 14Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 15University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 16McGill University, Montreal, QC, Canada, 17Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, 18NIH, Bethesda, MD, 19University of Bath, Bath, United Kingdom, 20NIH, NIEHS, Chapel Hill, NC, 21IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, 22Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 23Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 24National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, 25University Medical Center Goettingen, Göttingen, Germany, 26University of Milano Bicocca, Milan, Italy, 27Universitat Autònoma of Barcelona, Barcelona, Spain, 28University of Pennsylvania, Wynnewood, PA, 29University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, 30Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: The prevalence of cardiac manifestations has not been comprehensively described in anti-synthetase syndrome (ASSD). In the current study, we report the prevalence of cardiac…
  • Abstract Number: 0302 • ACR Convergence 2024

    TNFAIP3 Loss-of-function and Missense Mutations Demonstrate Clinically Diverse Presentations: A Multi-center Cohort Experience

    Elizabeth Kairis1, Manuel Carpio Tumba1, Urekha Karri1, Magdalena Harasimowicz1, Megan Cooper2, Lance Peterson2, Priscilla Campbell-Stokes3, Juan Carlos Aldave-Becerra4, Ana Beatriz Muñoz-Urribarri4 and Daniella Schwartz1, 1University of Pittsburgh, Pittsburgh, PA, 2Washington University School of Medicine, St. Louis, MO, 3Child Health Service, Hutt Hospital, National Pediatric Rheumatologic Service, Te Whatu Ora, New Zealand, 4Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru

    Background/Purpose: A20 is a critical anti-inflammatory protein encoded by the TNFAIP3 (tumor necrosis factor alpha-induced protein 3) gene. A20 negatively regulates multiple anti-inflammatory pathways including…
  • « Previous Page
  • 1
  • …
  • 76
  • 77
  • 78
  • 79
  • 80
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology